Vascor

arthrography, peripheral arteriography, intravenous excretory urography + 11 more
Treatment
13 FDA approvals
20 Active Studies for Vascor

What is Vascor

Iothalamic acidThe Generic name of this drug
Treatment SummaryIothalamic acid is a medical agent containing iodine that is used to help identify and diagnose medical issues.
Glofil-125is the brand name
Vascor Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Glofil-125
Iothalamic acid
1983
7

Approved as Treatment by the FDA

Iothalamic acid, otherwise called Glofil-125, is approved by the FDA for 13 uses which include Kidney Diseases and venography .
Kidney Diseases
venography
computerized tomography
peripheral arteriography
Bone structure of cranium
Chronic Kidney Disease (CKD)
Glomerular Filtration Rate (GFR)
arthrography
cerebral angiography
Endoscopic Retrograde Cholangiopancreatography
Cholangiography
angiogram
intravenous excretory urography

When to interrupt dosage

The proposed dose of Vascor is contingent upon the diagnosed condition, including cerebral angiography, venography and cystourethrography. The measure of dosage shifts in accordance with the technique of delivery (e.g. Solution or Intra-arterial; Intravenous) featured in the table beneath.
Condition
Dosage
Administration
arthrography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
peripheral arteriography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
intravenous excretory urography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
venography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
computerized tomography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
cerebral angiography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
retrograde cystography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
angiogram
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Bone structure of cranium
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Chronic Kidney Disease (CKD)
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Endoscopic Retrograde Cholangiopancreatography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Glomerular Filtration Rate (GFR)
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
cystourethrography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Cholangiography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous

Warnings

Vascor Contraindications
Condition
Risk Level
Notes
myelography
Do Not Combine
Pancreatitis
Do Not Combine
Prothrombin time prolongation
Do Not Combine
Endoscopy (procedure)
Do Not Combine
infection near the joint
Do Not Combine
Blood Coagulation Disorders
Do Not Combine
Cholangitis
Do Not Combine
There are 20 known major drug interactions with Vascor.
Common Vascor Drug Interactions
Drug Name
Risk Level
Description
Acrivastine
Minor
Iothalamic acid may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Iothalamic acid may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Almasilate
Minor
Iothalamic acid may decrease the excretion rate of Almasilate which could result in a higher serum level.
Antihemophilic factor (recombinant), PEGylated
Minor
Iothalamic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antithrombin III human
Minor
Iothalamic acid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.

Vascor Novel Uses: Which Conditions Have a Clinical Trial Featuring Vascor?

At present, 236 active clinical trials are assessing the effectiveness of Vascor in venography, Glomerular Filtration Rate (GFR) and angiogram.
Condition
Clinical Trials
Trial Phases
cystourethrography
0 Actively Recruiting
peripheral arteriography
0 Actively Recruiting
Endoscopic Retrograde Cholangiopancreatography
0 Actively Recruiting
cerebral angiography
0 Actively Recruiting
Bone structure of cranium
0 Actively Recruiting
Chronic Kidney Disease (CKD)
25 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 4, Phase 1
intravenous excretory urography
0 Actively Recruiting
angiogram
0 Actively Recruiting
Glomerular Filtration Rate (GFR)
0 Actively Recruiting
Cholangiography
0 Actively Recruiting
venography
0 Actively Recruiting
computerized tomography
1 Actively Recruiting
Not Applicable
retrograde cystography
0 Actively Recruiting
arthrography
0 Actively Recruiting

Patient Q&A Section about vascor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who owns VASCOR ltd?

"VASCOR is a privately held joint venture between APL Logistics and Fujitrans Corporation. It is infused with expertise that comes from the connection to its owners' global supply chain solutions in more than 50 countries across six continents, which includes overseas subsidiaries and partners."

Answered by AI

Who manufactures vascor?

"The text is talking about the joint venture between two companies, APL Logistics and Fujitrans Corporation."

Answered by AI

Clinical Trials for Vascor

Have you considered Vascor clinical trials? We made a collection of clinical trials featuring Vascor, we think they might fit your search criteria.
Have you considered Vascor clinical trials? We made a collection of clinical trials featuring Vascor, we think they might fit your search criteria.
Have you considered Vascor clinical trials? We made a collection of clinical trials featuring Vascor, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security